Dr. Jennifer Williams McVige, MD

Dr. McVige practices at Dent Neurologic Institute in Amherst, New York.

Dr. McVige's NPI, 1649596495, was assigned on April 19, 2010. Dr. McVige graduated from Jacobs School of Medicine and Biomedical Sciences in 2005. Dr. McVige holds New York license 257529.

Dr. McVige's primary practice is Dent Neurologic Institute, at 3980 Sheridan Dr, Amherst, NY 14226-1727. The practice phone is (716) 250-2000.

Dr. McVige's primary practice is Dent Neurologic Institute in Amherst, New York. The medical group on file is DENT Neurologic Institute.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McVige practices. Vendor and product names are available with a free account.

Neurology is Dr. McVige's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. McVige is board certified in neurology with special qualification in child neurology by the American Board of Psychiatry and Neurology. Dr. McVige is licensed in New York.

Dmand AI lists cerebrovascular disease, epilepsy, fibromyalgia and chronic pain, lower back pain, migraine and chronic headache, muscle pain, fibromyalgia, and limb pain and sleep apnea among the conditions Dr. McVige treats.

CMS data shows 4,155 Medicare services from Dr. McVige across 12 procedure codes in 2024, for 141 Medicare patients. Medicare paid $163,069 for them. Every service was in an office.

CMS counts 141 Medicare patients who saw Dr. McVige in 2024. The largest group is under 65, with 60 patients. 67% of them have high cholesterol, and 51% have high blood pressure. 33% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. McVige's median patient age at 25, with 72% women.

In 2024, Dr. McVige wrote 211 Medicare Part D claims for 51 patients. 46% of them were for generic drugs. CMS names the drug for 112 of them, across 6 drugs with 11 or more claims each, at $83,650 in total drug cost. In 2023, CMS named 127 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 44 out of 100 for Dr. McVige for performance year 2024, reported as part of a group. Dr. McVige accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McVige as offering telehealth.

Dmand AI links 23 papers to Dr. McVige, published from 2019 to 2025. 2024 was the busiest year, with 3. The most frequent topics are Migraine Disorders, Neuroimaging and Double-Blind Method. Dr. McVige has published most often in Cephalalgia. Dr. McVige's most frequent co-authors are Laszlo L. Mechtler, MD, Andrew D. Hershey, MD and Samantha Lee Irwin, BAO, BCH, MB.

Dmand AI links Dr. McVige to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Headache, Migraine Disorders and Pain. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. McVige that name 2 trials.

CMS Open Payments shows 3,233 general payments to Dr. McVige from 80 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Abbvie Inc. paid the most, $297,596. It also lists 24 research payments totaling $30,298 from 2018 to 2024, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. McVige, most recently CMS Stage 1 EHR in 2013.

Dr. McVige graduated from Jacobs School of Medicine and Biomedical Sciences in 2005.

Dr. McVige is in network with 17 carriers, including Aetna, Elevance and MVP Health Care. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.